RESILIENT第二部分:脂质体伊立替康对比拓扑替康治疗复发小细胞肺癌的随机开放标签III期研究
RESILIENT III期试验将461例一线铂类化疗后进展的小细胞肺癌患者随机分配至脂质体伊立替康组(229例)或拓扑替康组(232例),主要终点总生存期两组相似(7.9个月 vs 8.3个月,HR 1.11,P=0.31),未达到主要终点;脂质体伊立替康客观缓解率高于拓扑替康(44.1% vs 21.6%),≥3级相关不良事件发生率较低(42.0% vs 83.4%)。
要点
- 脂质体伊立替康与拓扑替康中位总生存期相似(7.9个月 vs 8.3个月,HR 1.11,P=0.31),主要终点未达到。
- 脂质体伊立替康客观缓解率44.1%,拓扑替康21.6%。
- 脂质体伊立替康≥3级相关不良事件发生率42.0%,拓扑替康83.4%。
核心结论
- 脂质体伊立替康与拓扑替康在复发小细胞肺癌患者中显示相似的中位总生存期和无进展生存期。
- 主要终点总生存期未达到,但脂质体伊立替康的客观缓解率高于拓扑替康。
- 脂质体伊立替康的安全性与其已知安全性一致,未出现新的安全性问题。
研究设计与样本
- RESILIENT是一项随机、开放标签、III期试验,比较二线脂质体伊立替康与拓扑替康治疗小细胞肺癌。
- 一线铂类化疗期间或之后进展的小细胞肺癌患者按1:1随机分配。
- 脂质体伊立替康组229例,拓扑替康组232例,共461例。
主要发现
- 中位随访18.4个月,脂质体伊立替康组中位总生存期7.9个月 vs 拓扑替康组8.3个月(HR 1.11,95%CI 0.90-1.37,P=0.31)。
- 盲法独立中心审查的中位无进展生存期:脂质体伊立替康组4.0个月 vs 拓扑替康组3.3个月(HR 0.96,95%CI 0.77-1.20,名义P=0.71)。
- 盲法独立中心审查的客观缓解率:脂质体伊立替康组44.1%(95%CI 37.6-50.8)vs 拓扑替康组21.6%(95%CI 16.4-27.4)。
- ≥3级相关治疗中出现的不良事件发生率:脂质体伊立替康组42.0% vs 拓扑替康组83.4%。
- 最常见的≥3级相关治疗中出现的不良事件:脂质体伊立替康组为腹泻(13.7%)、中性粒细胞减少(8.0%)和中性粒细胞计数降低(4.4%);拓扑替康组为中性粒细胞减少(51.6%)、贫血(30.9%)和白细胞减少(29.1%)。
关键数值与推荐
- 脂质体伊立替康给药方案:静脉注射70 mg/m2,每2周一次,6周为一周期。
- 拓扑替康给药方案:静脉注射1.5 mg/m2,每日一次连续5天,每3周一次,6周为一周期。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The phase III RESILIENT trial compared second-line liposomal irinotecan with topotecan in patients with small cell lung cancer (SCLC). PATIENTS AND METHODS: Patients with SCLC and progression on or after first-line platinum-based chemotherapy were randomly assigned (1:1) to intravenous (IV) liposomal irinotecan (70 mg/m2 every 2 weeks in a 6-week cycle) or IV topotecan (1.5 mg/m2 daily for 5 consecutive days, every 3 weeks in a 6-week cycle). The primary end point was overall survival (OS). Key secondary end points included progression-free survival (PFS) and objective response rate (ORR). RESULTS: Among 461 randomly assigned patients, 229 received liposomal irinotecan and 232 received topotecan. The median follow-up was 18.4 months. The median OS was 7.9 months with liposomal irinotecan versus 8.3 months with topotecan (hazard ratio [HR], 1.11 [95% CI, 0.90 to 1.37]; P = .31). The median PFS per blinded independent central review (BICR) was 4.0 months with liposomal irinotecan and 3.3 months with topotecan (HR, 0.96 [95% CI, 0.77 to 1.20]; nominal P = .71); ORR per BICR was 44.1% (95% CI, 37.6 to 50.8) and 21.6% (16.4 to 27.4), respectively. Overall, 42.0% and 83.4% of patients receiving liposomal irinotecan and topotecan, respectively, experienced grade ≥3 related treatment-emergent adverse events (TEAEs). The most common grade ≥3 related TEAEs were diarrhea (13.7%), neutropenia (8.0%), and decreased neutrophil count (4.4%) with liposomal irinotecan and neutropenia (51.6%), anemia (30.9%), and leukopenia (29.1%) with topotecan. CONCLUSION: Liposomal irinotecan and topotecan demonstrated similar median OS and PFS in patients with relapsed SCLC. Although the primary end point of OS was not met, liposomal irinotecan demonstrated a higher ORR than topotecan. The safety profile of liposomal irinotecan was consistent with its known safety profile; no new safety concerns emerged.
引用
- Spigel DR, Dowlati A, Chen Y, et al. RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer. J Clin Oncol. 2024. PMID: 38648575. doi:10.1200/JCO.23.02110
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。